FDA and Omnibus Bill Impact on Medical Device Security

This document is a technical report that outlines the implications of the FDA's approach to medical device cybersecurity following the December 2022 Omnibus Bill. It details the expected changes in premarket and post-market security requirements for medical devices, emphasizing the importance of Software Bill of Materials (SBOM) management. The report explains how manufacturers must enhance their cybersecurity protocols to comply with new regulations, including monitoring third-party software components for vulnerabilities throughout the product lifecycle. It discusses the necessity for robust software lifecycle processes, including risk management programs and documentation consistent with Quality System Regulations. The report also highlights the critical role of vulnerability management and incident response in ensuring device safety and security. Additionally, it addresses the need for manufacturers to establish effective communication processes for vulnerability intake and handling, ensuring that stakeholders are informed about potential risks associated with medical devices. Overall, the document serves as a guide for manufacturers navigating the evolving landscape of medical device cybersecurity.